H0165

7-Ethyl-10-hydroxycamptothecin

Name: 7-Ethyl-10-hydroxycamptothecin
Brand: SIGMA
Price: 242 EUR

powder, ≥98% (HPLC)

Synonym(e):

SN-38

Slide 1 of 2

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

10 MG

€ 242,00

50 MG

€ 826,00

€ 242,00

Warenkorb auf Verfügbarkeit prüfen

Über diesen Artikel

Empirische Formel (Hill-System):

C₂₂H₂₀N₂O₅

CAS-Nummer:

86639-52-3

Molekulargewicht:

392.40

UNSPSC Code:

12352204

PubChem Substance ID:

329815105

NACRES:

NA.77

MDL number:

MFCD00871873

Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

Technischer Dienst

Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.

Unterstützung erhalten

Produktname

7-Ethyl-10-hydroxycamptothecin, ≥98% (HPLC), powder

biological source

Artemisia annua

Quality Level

200

assay

≥98% (HPLC)

form

powder

solubility

DMSO: 1 mg/mL

storage temp.

−20°C

SMILES string

OC1=CC2=C(CC)C(C3)=C(N=C2C=C1)C(N3C4=O)=CC5=C4COC([C@]5(O)CC)=O

InChI

1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1

InChI key

FJHBVJOVLFPMQE-QFIPXVFZSA-N

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel	A3731	SML2607	P4904
Sigma-Aldrich H0165 7-Ethyl-10-hydroxycamptothecin	A3731 Artesunate	Sigma-Aldrich SML2607 Clevidipine Butyrate	Sigma-Aldrich P4904 β-Acetyl-γ-O-hexadecyl-L-α-phosphatidylcholine hydrate
assay ≥98% (HPLC)	assay -	assay ≥98% (HPLC)	assay ≥98%
biological source Artemisia annua	biological source Artemisia annua	biological source -	biological source -
Quality Level 200	Quality Level 100	Quality Level -	Quality Level 200
form powder	form crystalline powder	form powder	form powder
solubility DMSO: 1 mg/mL	solubility acetone: 33.4 mg/mL	solubility DMSO: 2 mg/mL, clear	solubility -
storage temp. −20°C	storage temp. room temp	storage temp. 2-8°C	storage temp. −20°C

Application

7-Ethyl-10-hydroxycamptothecin has been used:

to inhibit enterovirus 71 (EV71) (H) infection[1]
to screen the chemosensitivity of pancreatic adenocarcinoma cells[2]
as a chemical to study its ability to reverse multidrug resistance (MDR), due to ATP binding cassette (ABC) transporters[3]

Biochem/physiol Actions

Active metabolite of irinotecan. Inhibitor of topoisomerase I.

Active metabolite of irinotecan. Inhibitor of topoisomerase I.. Gene expression analysis of colon cancer cell lines treated with SN-38 showed differential effects: the majority of affected genes were down-regulated (including, most strongly, genes related to receptor and kinase activity, signal transduction, apoptosis, RNA processing, protein metabolism and transport, cell cycle and transcription. Some of the up-regulated genes were involved in apoptosis, transcription, development and differentiation.

pictograms

GHS08,GHS07

signalword

Danger

hcodes

H302,H360D,H372

pcodes

P201 - P202 - P260 - P264 - P301 + P312 - P308 + P313

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B - STOT RE 1

target_organs

Gastro-intestinal system

Lagerklasse

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

0000540986

0000522612

0000494085

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Dual roles for splice variants of the glucuronidation pathway as regulators of cellular metabolism.

Mélanie Rouleau et al.

Molecular pharmacology, 85(1), 29-36 (2013-10-22)

Transcripts of the UGT1A gene, encoding half of human UDP-glucuronosyltransferase (UGT) enzymes, undergo alternative splicing, resulting in active enzymes named isoforms 1 (i1s) and novel truncated isoforms 2 (i2s). Here, we investigated the effects of depleting endogenous i2 on drug

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

Shuichi Hironaka et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(35), 4438-4444 (2013-11-06)

This phase III study compared treatment with weekly paclitaxel and biweekly irinotecan in patients with advanced gastric cancer refractory to treatment with fluoropyrimidine plus platinum. Patients were randomly assigned to receive either paclitaxel (80 mg/m(2) on days 1, 8, and

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

Josep Tabernero et al.

European journal of cancer (Oxford, England : 1990), 50(2), 320-331 (2013-10-22)

The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen. In the

Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor.

Kan Xing Wu et al.

Antiviral research, 143, 122-133 (2017-04-22)

Enterovirus 71 (EV71) is one of the causative agents of hand, foot and mouth disease (HFMD) associated with severe neurological disease. EV71's pathogenesis remains poorly understood and the lack of approved antiviral has led to its emergence as a clinically

Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport.

Atish Patel et al.

Pharmacological research, 121, 184-193 (2017-04-30)

Cancer is a disease whose treatment is often limited due to the development of a phenomenon known as multidrug resistance (MDR). There is an immense demand for development of novel agents that can overcome the MDR in cancer. A group

Alle zugehörigen Dokumente anzeigen

Artikel

Graphene Oxide & Reduced Graphene Oxide Applications

Graphene oxide, a monomolecular layer of graphite with oxygen functionalities, holds unique properties valuable for various applications in materials science.

Global Trade Item Number

SKU	GTIN
H0165-10MG	04061833662748
H0165-50MG	04061833662779

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung

7-Ethyl-10-hydroxycamptothecin

powder, ≥98% (HPLC)

Größe auswählen

H0165-10MG

€ 242,00

Über diesen Artikel

Wichtige Dokumente

Fortfahren mit

Eigenschaften

Produktname

biological source

Quality Level

assay

form

solubility

storage temp.

SMILES string

InChI

InChI key

Ähnliche Artikel vergleichen

Dieser Artikel

Beschreibung

Application

Biochem/physiol Actions

Sicherheitshinweise

pictograms

signalword

hcodes

pcodes

Hazard Classifications

target_organs

Lagerklasse

wgk

flash_point_f

flash_point_c

ppe

Dokumentation

Analysenzertifikate (COA)

Besitzen Sie dieses Produkt bereits?

Peer-Reviewed-Artikel

Protokolle und Artikel

Artikel

Global Trade Item Number

Questions

Reviews

Active Filters

Technischer Dienst